PUBLISHER: Mordor Intelligence | PRODUCT CODE: 2184693
PUBLISHER: Mordor Intelligence | PRODUCT CODE: 2184693
According to Mordor Intelligence, the magnetic beads market size is projected to expand from USD 2.60 billion in 2025 and USD 2.85 billion in 2026 to USD 4.30 billion by 2031, registering a CAGR of 8.58% between 2026 and 2031.

Automated magnetic bead extraction is increasingly important in the magnetic beads market in molecular diagnostic laboratories that need repeatable processing and electronic documentation. QIAGEN states that its QIAsprint Connect system supports audit trails and secure electronic records designed for 21 CFR Part 11 readiness. Such functions are difficult to reproduce with manual spin-column steps, especially in regulated laboratory settings. QIAGEN launched QIAmini in September 2026 for laboratories that still process smaller batches manually. The launch shows that automated workflows are reaching lower-throughput research environments as well as high-volume testing centers. In the magnetic beads market, vendors that pair consumables with instruments can benefit from recurring reagent demand and more durable customer relationships.
Magnetic activated cell sorting remains a well-established practice in the magnetic beads market and a method for clinical-grade T-cell isolation and processing. Thermo Fisher stated in December 2024 that Dynabeads were used in more than 200 active clinical trials and several approved cell therapy products. Miltenyi's CliniMACS Prodigy integrates enrichment, activation, transduction, and expansion within a closed manufacturing workflow. This integration makes cell isolation part of a broader manufacturing platform rather than an isolated reagent choice. As production moves to larger commercial volumes, throughput can become a limiting issue for conventional magnetic processing. Detachable bead formats address this concern by allowing cells to be released after isolation, reducing residual-particle concerns in the final process.
Other drivers and restraints analyzed in the detailed report include:
For complete list of drivers and restraints, kindly check the Table Of Contents.
In vitro diagnostics held 43.35% of the magnetic beads market share in 2025, supported by high-volume nucleic acid extraction in clinical and reference laboratories. Magnetic capture supports automated DNA and RNA preparation across many molecular testing workflows. Life-science research was the second-largest application because researchers use beads in protein pull-downs, immunoprecipitation, and next-generation sequencing preparation. Environmental and food testing provided additional volume where pathogen screening is required. Drug delivery and therapeutics remained at an early commercial stage, even though magnetic nanocarrier systems have shown proof-of-concept results. A 2025 study described folic acid-conjugated magnetic nanoparticles for controlled doxorubicin release, while commercial scale-up still presents challenges.
Cell separation and therapy is projected to grow at a 9.89% CAGR through 2031, making it the fastest-growing application in the magnetic beads market. CAR-T and CAR-NK manufacturing requires controlled cell selection, activation, and expansion procedures. Miltenyi Bioindustry's work with BioOra and Immatics indicates that MACS-based processing is moving into commercial-phase cell therapy operations. The U.S. Food and Drug Administration issued guidance on CAR T cell product development in January 2024. The guidance supports investment in documented process controls and qualified bead-handling tools. The segment's demand will be tied to therapy approvals, manufacturing capacity, and the ability of CDMOs to deliver consistent batches.
Iron oxide accounted for 93.28% of segment revenue in 2025 because it combines superparamagnetic behavior, biocompatibility, and established use in diagnostic and bioprocessing settings. Decades of manufacturing refinement also support its broad acceptance across commercial bead formats. Cobalt ferrite offers higher coercivity but has toxicity constraints that limit its use in clinical applications. The supplied research places approximately 52% of high-purity iron oxide production capacity in Asia-Pacific. China and Japan remain important refining centers under this supply structure. This regional concentration can support nearby manufacturers while creating supply exposure for purchasers in other regions.
Nickel ferrite is projected to grow at a 9.38% CAGR through 2031, although its revenue base remains much smaller than iron oxide. Its magnetic saturation characteristics can support low-gradient separator designs for larger bioprocessing volumes. Conventional permanent-magnet systems can lose field uniformity when process volumes rise above 1 liter. Nickel ferrite is therefore relevant to separator and bead co-design rather than broad replacement of iron oxide. The magnetic beads market size for this material will depend on progress in large-volume magnetic separation. Its growth reflects focused materials development for specialized purification systems instead of a change in the core material hierarchy.
North America held 41.79% of the magnetic beads market share in 2025. The region benefits from a large base of cell and gene therapy clinical trials, established molecular diagnostics, and substantial pharmaceutical and biotechnology research activity. The United States generates demand from academic proteomics through commercial CAR-T manufacturing. These linked activities support consumption across research, clinical testing, and regulated production. South America remained a smaller contributor, although public health laboratory modernization in Brazil is creating additional diagnostic demand.
Europe was the second-largest regional market in 2025. Germany is both a production and consumption center, with Miltenyi Biotec, micromod Partikeltechnologie, and Merck KGaA's life science business contributing to the regional supplier base. The United Kingdom also has a growing cell and gene therapy manufacturing ecosystem. ISO/DIS 25802 reflects a higher focus on immunomagnetic bead quality control and could raise technical compliance requirements in Europe. These requirements can favor manufacturers with GMP capabilities while raising entry barriers for smaller suppliers. GenScript's European mRNA hub, established in March 2026, extends access to mRNA synthesis and purification infrastructure.
Asia-Pacific is expected to advance at a 10.03% CAGR through 2031, the fastest rate among regions. China's CAR-T pipeline and government-backed genomic medicine investment are increasing demand for cell-processing materials. The supplied research expects magnetic bead consumption in CAR-T manufacturing to double by 2031 from its 2026 base. Precision System Science's Magtration technology supports automated nucleic acid extraction and reduces reliance on imported workflows in Japan. India's healthcare modernization and growing CRO activity support future demand. South Korea, Australia, GCC countries, and other Middle East and African markets add demand through biotech investment, diagnostic upgrades, and hospital modernization.